ArticleFrontiers in medicine2026
The unregulated majority: who ensures quality in non-submission real-world studies?
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-world evidence (RWE) plays an increasingly important role in healthcare decision-making, yet most industry-sponsored RWE studies are not intended for regulatory or reimbursement submission. While many such studies are conducted rigorously, this non-submission evidence base often operates without consistent protocol pre-specification, analytical transparency, or structured oversight, creating variability in quality and credibility. This Policy Brief examines this governance blind spot and argues that the challenge is structural rather than individual or intentional. Drawing on regulatory pilots and harmonisation initiatives, it shows that tools to strengthen non-submission RWE already exist but are unevenly applied. A framework is proposed based on three pillars: protocol registration, analytical transparency, and proportionate internal governance, including accountability for patient-contributed data. Extending these safeguards beyond submission-grade studies would raise baseline RWE quality and strengthen trust in RWE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.